Arcus Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

RCUS$18.67-1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

Years ended December 31, 2025, 2024 and 2023

	Number of shares of common stock	Common stock and additionalpaid-in capital	Accumulated deficit	Accumulatedothercomprehensive income (loss)	Totalstockholders’ equity
Balance at December 31, 2022	72.9	$1,206	$(542)	$(7)	$657
Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 15, Stockholders' Equity)	1.2	25	—	—	25
Issuance of common stock in connection with our equity award programs	1.4	7	—	—	7
Stock-based compensation	—	73	—	—	73
Other comprehensive income	—	—	—	7	7
Net loss	—	—	(307)	—	(307)
Balance at December 31, 2023	75.5	1,311	(849)	—	462
Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 15, Stockholders' Equity)	15.2	228	—	—	228
Issuance of common stock in connection with our equity award programs	1.5	2	—	—	2
Stock-based compensation	—	76	—	—	76
Net loss	—	—	(283)	—	(283)
Balance at December 31, 2024	92.2	1,617	(1,132)	—	485
Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 15, Stockholders' Equity)	30.8	429	—	—	429
Issuance of common stock in connection with our equity award programs	2.3	10	—	—	10
Stock-based compensation	—	60	—	—	60
Net loss	—	—	(353)	—	(353)
Balance at December 31, 2025	125.3	$2,116	$(1,485)	$—	$631

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.